Cimeio therapeutics is a spin-off from the University of Basel. The scientific basis was born out of years of cutting-edge research by Professor Lukas Jeker–co-founder…
For non-European biopharmaceutical companies, launching a drug in the EU can be extremely challenging. but, with the right drug and a clear strategy, it can…
2022 started off on some good notes for BaseLaunch, with two new companies (one still in stealth) joining our portfolio and another one announcing the…
We are excited to welcome Aukera Therapeutics as our newest portfolio company! Basel, Switzerland., 15 February 2022 — Aukera Therapeutics is a spin-off from the Biozentrum…
We are excited to welcome Stromal Therapeutics as our newest portfolio company! Basel, Switzerland., 28 January 2022 — Stromal Therapeutics is emerging from one of…
FDA greenlights Alentis Phase 1 protocol study design Alentis to begin transition from pre-clinical to clinical Basel, Switzerland., 04 January 2022 — Alentis Therapeutics, AG…
Swiss biotech venture accelerator and incubator BaseLaunch was started in 2017 to help launch and grow the next generation of biotech companies. The accelerator has…